Introduction
Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning (RIC) or nonmyeloablative conditioning has been an effective treatment for many patients with hematological malignancies, as well as for selected patients with solid cancers or inherited blood disorders.
A number of different RIC or nonmyeloablative conditioning regimens have been explored. The separation of what constitutes a nonmyeloablative versus a RIC regimen is somewhat arbitrary (Table 1) , although Giralt proposed some criteria for nonmyeloablative conditioning that included (1) no eradication of host hematopoiesis, (2) prompt hematologic recovery (o4 weeks) without transplant and (3) presence of mixed chimerism upon engraftment. 1 Similarly, the distinction between RIC and myeloablative conditioning has been discussed; the criteria proposed by Giralt 1 included p5 Gy total body irradiation (TBI), p9 mg/kg busulfan dose, p140 mg/m 2 melphalan dose and p10 mg/kg thiothepa dose. 1 RIC regimens have combined modest doses of fludarabine (used mainly for its immunosuppressive activity) with consequent (but nonmyeloablative) doses of alkylating agents such as melphalan (140 mg/m 2 ) 2 or busulfan (4-8 mg/kg), 3 given to produce major anti-tumor effects with the hope of controlling the malignancy before the occurrence of the immune-mediated graft-versus-tumor effects. In contrast, nonmyeloablative conditioning has used potent immunosuppressive regimens to overcome host-versus-graft reactions (graft rejection), 4, 5 allowing engraftment of donor hematopoietic and immune cells. Thus, following nonmyeloablative conditioning, eradication of both host hematopoiesis and tumor cells is mediated nearly exclusively by immune-mediated graft-versushost effects. 6, 7 The degree of myelosuppression induced by RIC or nonmyeloablative regimens has varied from one regimen to another, those including intermediate doses of either busulfan (8 mg/kg) or melphalan (140 mg/m 2 ) being the most myelosuppressive, whereas the one using low-dose TBI (2 Gy) with or without fludarabine being the least myelosuppressive ( Figure 1 and Table 1 ). 16 We compared erythropoietic activity in patients given allogeneic grafts after either myeloablative (n ¼ 57) or nonmyeloablative (n ¼ 54) conditioning (Figure 2) . 17 plus fludarabine (90 mg/m 2 , n ¼ 5). Erythropoietic activity was quantified by assessing the levels of the serum soluble transferrin receptor (sTfR, a quantitative marker of total erythropoietic activity). After myeloablative conditioning, erythropoietic activity decreased sharply and remained abnormally low the first month after HCT. In contrast, erythropoietic activity remained consistently above the lower limit of normal values after nonmyeloablative conditioning, demonstrating that the regimens were indeed mildly myelosuppressive.
In this article, we first describe what is currently known about red blood cell (RBC) and platelet transfusion requirements after RIC or nonmyeloablative conditioning, and then review which factors are associated with increased transfusion requirements. In the second part of the review, we discuss the potential role of hematopoietic growth factors such as erythropoietin (Epo) or granulocyte colony-stimulating factor (G-CSF) after nonmyeloablative or RIC HCT.
RBC transfusions

RBC transfusion requirements
Given that some degree of erythropoietic activity persists after nonmyeloablative conditioning, 17 it was expected that patients receiving nonmyeloablative conditioning would require less RBC transfusions than those given myeloablative regimens. Indeed, several studies found decreased RBC transfusion requirements after nonmyeloablative conditioning or RIC in comparison to what is seen after myeloablative conditioning. [18] [19] [20] Weissinger et al. 18 compared RBC transfusions in patients given allogeneic peripheral blood stem cells (PBSC) from human leukocyte antigen (HLA)-identical siblings after nonmyeloablative (n ¼ 40) versus myeloablative (n ¼ 67) conditioning. Nonmyeloablative conditioning consisted of 2 Gy TBI with (n ¼ 10) or without (n ¼ 30) added fludarabine (90 mg/m 2 ). Sixty-three percent of the nonmyeloablative recipients required RBC transfusions compared to 96% of those given myeloablative conditioning (P ¼ 0.0001). Furthermore, the number of RBC units transfused was reduced in nonmyeloablative recipients with a median of 2 (range, 0-50) units transfused versus 6 (range, 0-34) in those receiving myeloablative conditioning (P ¼ 0.0001). High transfusion requirements before HCT (P ¼ 0.0005) and donor-recipient ABO incompatibility (major mismatch, P ¼ 0.0001) were each associated with increased RBC transfusion requirements in both patient groups. Similar findings were found by Sorror et al. 19 comparing data from patients given HLA-matched unrelated grafts after nonmyeloablative (consisting of 2 Gy TBI plus fludarabine, n ¼ 60) versus myeloablative conditioning (n ¼ 74). Specifically, 88% of nonmyeloablative recipients received a median of three RBC transfusions compared to 100% myeloablative recipients, who required a median of five RBC transfusions (P ¼ 0.005).
Ivanov et al. 20 analyzed RBC transfusion requirements in 110 consecutive patients given grafts from HLA-identical siblings after RIC (n ¼ 64; consisting of fludarabine 180 mg/m 2 , oral busulfan 8 mg/kg and various doses of anti-thymocyte globulins (ATG)) or myeloablative conditioning (n ¼ 46). Postgrafting immunosuppression included cyclosporine (CSP) given alone in all RIC recipients and in 18 of 46 myeloablative recipients, or combined with short methotrexate (MTX) in 28 myeloablative recipients. Eighty-nine percent of the patients given RIC required RBC transfusions compared to 100% of myeloablative recipients. In addition, the number of RBC units transfused was significantly reduced in RIC recipients, with a median of 4 (range, 0-28) units transfused versus 12 (range, 2-56) in those given myeloablative conditioning (Po0.0001). In multivariate analysis, high RBC transfusion requirements were independently predicted by myeloablative conditioning versus RIC (P ¼ 0.0005), and marrow versus PBSC as stem cell source (Po0.0001). Further, among RIC recipients, low hemoglobin (Hb) levels before HCT (Po0.0001) and high ATG doses (P ¼ 0.009) were each independently associated with high RBC transfusion requirements.
Le Blanc et al. 21 analyzed data from 58 patients given grafts after nonmyeloablative conditioning (n ¼ 2 ) or busulfan (10 mg/kg). Postgrafting immunosuppression combined CSP and short MTX. The main factor increasing RBC transfusion requirements was the occurrence of severe acute graft-versus-host disease (GVHD). Specifically, patients with grade III-IV acute GVHD (n ¼ 12) required a median of 15 (range, RBC units the first 100 days after HCT, whereas patients without grade III-IV acute GVHD (n ¼ 65) received a median of 2 (range, 0-14) RBC units (Po0.01). In patients without grade III-IV acute GVHD, RBC transfusion requirements until day 100 after HCT were higher in patients with major ABO mismatch than in those given ABOcompatible grafts (P ¼ 0.02).
Taken together, these studies suggested that intensity of the conditioning regimen, Hb levels before HCT, stem cell source, acute GVHD and major ABO mismatch affected RBC transfusion requirements after nonmyeloablative or RIC HCT ( Table 2 ).
The case of ABO incompatibility ABO antigens are potent immunogens expressed on the surface of RBC, RBC progenitors/precursors and also on the surface of a number of nonhematopoietic cells. Although the ABO group Abbreviations: ATG, anti-thymocyte globulin; RIC, reduced-intensity conditioning; TBI, total body irradiation. [2] Regimens are classified from less to more myelosuppressive. Note that this classification is not based on direct experimentation, and is thus hypothetical. Criteria for RIC included p5 Gy TBI, p9 mg/kg busulfan, p140 mg/m 2 melphalan and p10 mg/kg thiothepa. 1 system has been of critical importance in transfusion medicine, it has had little impact on HCT outcomes after myeloablative conditioning. 23 Indeed, although the presence of a major ABO mismatch between donor and recipient was associated with delayed recovery of erythropoietic activity and occurrence of pure red cell aplasia, it did not have any impact on the incidence of grade II-IV acute GVHD or on overall survival. 23 The mechanisms of erythropoietic impairment in case of ABO mismatch after myeloablative conditioning have not been completely elucidated, but include direct inhibition of donor erythropoiesis by residual host-derived anti-ABO isohemagglutinins (HA), 24 even if virtually all host-derived hematopoiesis (including plasma cells producing anti-donor HA) has been eradicated by the conditioning regimen.
As an important characteristic of many nonmyeloablative regimens has been the persistence of a certain amount of hostderived hematopoiesis (including B-cell lymphopoiesis) for up to 6-12 months after HCT, 4, 6, 25 it has been hypothesized that delayed disappearance of host plasma cells producing antidonor HA might lead to particularly delayed donor erythropoiesis, and a high frequency of pure red cell aplasia, after ABO-incompatible nonmyeloablative HCT.
Supporting this hypothesis, Bolan et al. 26 found that donor RBC chimerism (defined as the initial detection of donor RBCs in peripheral blood) was markedly delayed following nonmyeloablative (n ¼ 14) versus myeloablative (n ¼ 12) conditioning (median, 114 versus 40 days; Po0.0001) in patients with major ABO incompatibility with their donor. Further, four out of 14 nonmyeloablative versus zero out of 12 myeloablative recipients experienced pure red cell aplasia (P ¼ 0.10). Interestingly, donor RBC chimerism closely correlated with decreasing host anti-donor HA levels. The latter disappeared more slowly after nonmyeloablative than after myeloablative conditioning (median, 83 versus 44 days; P ¼ 0.03). In addition, CSP discontinuation induced potent graft-versus-plasma cell effects, and allowed resolution of pure red cell aplasia in all four patients. The existence of a graft-versus-plasma cell effect was further supported by the observation that severe acute GVHD was associated with a rapid decrease in anti-donor HA titers in two patients, in agreement with a previous study by Mielcarek et al. 27 showing faster decrease in anti-donor HA in patients developing acute GVHD than in those without acute GVHD, after myeloablative conditioning. However, a recent study described the persistence of significant percentages of recipientderived plasma cells in patients with pure red cell aplasia after nonmyeloablative conditioning, despite full donor T-cell and granulocyte chimerisms. 28 This suggests that host-derived plasma cells might be less susceptible than host-derived T cells or myeloid cells to donor-derived alloreactive T cells. 29 In agreement with the study of Bolan et al., 26 Zaucha et al.
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found that the median time to reach HA titers o1:1 was at least 133 days in patients given ABO-incompatible grafts after nonmyeloablative conditioning, approximately twice longer than after myeloablative conditioning. Further, donor erythropoiesis was effective only when low or absent anti-donor HA titers were achieved. Finally, it should be emphasized that some RIC regimens, particularly those containing alemtuzumab, are likely to eradicate most of the host-derived anti-donor HA-producing plasma cells, and thus might not be associated with delayed donor RBC chimerism in comparison to what is seen with myeloablative conditioning. 31 
Platelet transfusions
Several studies have found lower platelet transfusion requirements in patients given nonmyeloablative conditioning or RIC than in those receiving a myeloablative regimen. 18, 19 Weissinger et al.
18 studied platelet transfusion requirements in patients given allogeneic PBSC from HLA-identical siblings after nonmyeloablative (n ¼ 40) versus myeloablative (n ¼ 67) conditioning. Nonmyeloablative conditioning consisted of 2 Gy TBI with (n ¼ 10) or without (n ¼ 30) added fludarabine (90 mg/m 2 ). Twenty-three percent of nonmyeloablative recipients required platelet transfusions compared to 100% of those given myeloablative conditioning (Po0.0001). Further, the number of platelet units given was reduced after nonmyeloablative conditioning, with a median of 0 (range, 0-214) units transfused versus 24 (range, 4-358) after myeloablative conditioning (Po0.0001). High platelet transfusion requirements before HCT were also associated with increased transfusion requirements in both patient groups (P ¼ 0.01).
Sorror et al. 19 analyzed transplantation-related toxicities including transfusion requirements after HLA-matched unrelated HCT in 134 concurrent patients given either nonmyeloablative (n ¼ 60) or myeloablative (n ¼ 74) conditioning. Sixty-three percent of nonmyeloablative patients received a median of and occurrence of grade III-IV acute GVHD (P ¼ 0.0001) were associated with increased requirements for platelet transfusions.
Potential role for hematopoietic growth factors
Epo
Epo is the key regulatory factor of erythropoiesis, and acts mainly by preventing apoptosis of late erythroid progenitors. In normal patients, serum Epo levels increase exponentially with decreasing Hb levels. After myeloablative allogeneic HCT, serum Epo levels first rapidly increased to disproportionately high levels for 1-3 weeks and then became inappropriately low for the degree of anemia, resulting in low erythropoietic activity and prolonged anemia. 32 As predicted by these observations, Epo therapy offered minimal benefit when started immediately after HCT, 33 but was quite efficient when started more than 4 weeks after HCT, 34 that is, when serum Epo production became impaired.
There are two important differences in the physiology of erythropoiesis following nonmyeloablative versus myeloablative conditioning. First, a certain amount of host erythropoietic activity persists after nonmyeloablative conditioning (Figure 2 ), suggesting that Epo therapy might be efficient even when started on day 0 after nonmyeloablative HCT. Secondly, contrary to endogeneous Epo deficiency observed after myeloablative Figure 3 Hb values and sTfR levels after nonmyeloablative HCT in patients given (n ¼ 46) or not given (control group, n ¼ 14) rHuEpo. Values are normalized relative to their value on the day of transplantation. The right panels provide the evolution in Epo group 1 (rHuEpo started on day 0; n ¼ 19) and left panels the evolution in Epo group 2 (rHuEpo started on day 30; n ¼ 27). P-values are given for comparisons with the control group at any particular time point by Student's t-tests (*o0.05,**o0.01, ***o0.001). Reproduced with permission from Vanstraelen et al.
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Transfusions after RIC F Baron et al conditioning, Epo production remains adequate for the degree of anemia throughout the post-transplant period after nonmyeloablative conditioning, suggesting that Epo therapy might be less efficient after nonmyeloablative than after myeloablative conditioning, when started after 4 weeks following transplantation. 17 Two recent studies have investigated the use of Epo after nonmyeloablative conditioning or RIC. 35, 36 Ivanov et al. 35 gave Epo (either 30 000 IU epoetin-beta or 150 mg darbepoetinealpha per week, started on day 1) to 20 consecutive patients following RIC allogeneic HCT (Epo group). Conditioning combined fludarabine, busulfan and ATG. Epo therapy was continued until the Hb level reached 14 g/dl or until day 60. Twenty-seven matched patients not receiving recombinant human erythropoietin (rHuEpo) served as controls (control group). Median Hb levels on days 30 and 60 after HCT were 11.6 and 12.8 g/dl in the Epo group versus 10.0 g/dl (P ¼ 0.0001) and 9.9 g/dl (Po0.0001) in the control group, respectively. In addition, there was a trend for lower RBC transfusion requirements in the Epo group (median 2 units (range, 2-4 units)) compared to the control group (median 4 units (range, 2-12 units); P ¼ 0.07).
We analyzed erythropoietic activity (assessed by sTfR levels) and Hb levels in 60 patients given allogeneic grafts after nonmyeloablative conditioning. 36 Fourteen patients did not receive Epo (control group), 19 were given Epo from day 0 after HCT (Epo group 1), whereas 27 were scheduled to start Epo on day 28 after HCT (Epo group 2). Recombinant human Epo was administered subcutaneously at a dose of 500 U/kg/week, with the aim of achieving Hb levels of 13 g/dl. During the first month as well as between days 30 and 180, sTfr levels and Hb values were significantly higher in patients receiving rHuEpo compared to those not receiving it (Figure 3) . However, transfusion requirements were significantly decreased only during the first month in patients given Epo from day 0 (Epo group 1, P ¼ 0.0169). Interestingly, donor T-cell chimerism levels above 60% on day 42 was the best predictor of achieving Hb values 413 g/dl, suggesting possible inhibition of donor erythropoiesis by residual recipient lymphocytes, in patients with low donor T-cell chimerism levels.
Taken together, these studies indicated that giving Epo (either 30 000 IU epoetin or 150 mg darbepoetin-alpha per week) early after nonmyeloablative or RIC HCT could reduce RBC transfusion needs. A prospective randomized trial is ongoing at our center, with Epo starting around day 0, to assess its clinical benefit in terms of transfusion requirements and quality of life. However, until the clinical benefits of Epo therapy in this setting are clearly demonstrated, its use should be restricted to patients included in clinical trials.
G-CSF
G-CSf has been administered to hasten neutrophil recovery after myeloablative allogeneic HCT, and its potential impact on immune recovery and GVHD incidence has been extensively debated (reviewed by Mohty et al. 37 ). However, no study thus far analyzed the impact of G-CSF use after nonmyeloablative conditioning or RIC. Some groups of investigators gave G-CSF in most patients, 2, 38 whereas others either did not use it or gave it only in case of granulocytopenia. 5, 39, 10 In one study, in which RIC consisted of fludarabine (150 mg/m 2 ), melphalan (140 mg/ m 2 ) and alemtuzumab (100 mg) and postgrafting immunosuppression of CSP alone, there was a suggestion that time to neutrophil recovery could be 1 day shorter in patients given G-CSF at 5 mg/kg/day (1373 days, n ¼ 32) compared to those not given G-CSF (1474 days, n ¼ 6) (NS). Prospective randomized studies are therefore needed to clarify the impact of G-CSF administration on HCT outcome after nonmyeloablative or RIC regimens.
Conclusion
Despite the fact that nonmyeloablative and RIC regimens are associated with lower transfusion requirements than myeloablative ones, most patients given nonmyeloablative conditioning or RIC required RBC and/or platelet transfusions. Predictive factors for high transfusion requirements include low Hb or platelet values before HCT, intensity of the conditioning regimen, use of marrow instead of PBSC as stem cell source, occurrence of severe acute GVHD and major ABO mismatch (for RBC transfusions). In case of major ABO incompatibility, donor erythroid engraftment is further delayed after nonmyeloablative compared to myeloablative conditioning, because of the persistence of anti-donor HA-secreting host-derived plasma cells for up to several months after nonmyeloablative conditioning. The potential role of hematopoietic growth factors such as Epo, G-CSF, thrombopoietin or thrombopoietin receptor ligands (such as the AMG 531, which has shown promising activity in patients with immune thrombocytopenic purpura) 40 warrants further investigations. Their rational use might allow performing nonmyeloablative or RIC HCT without RBC and platelet transfusions in most patients.
